Biogen Inc. stock gains as Canada backs reimbursement for Alzheimer drug Leqembi

Biogen Inc. stock is trading higher after Canada’s national drug agency recommended public reimbursement for the Alzheimer treatment Leqembi, adding a fresh regulatory tailwind to recent earnings figures and guidance.

Biogen Inc. (ISIN US09062X1037) stock is trading higher as of September 1, 2026, helped by a positive reimbursement recommendation in Canada for the Alzheimer therapy Leqembi and supported by recent earnings figures that frame expectations for the biotech’s pipeline-driven growth.

Canadian reimbursement boost for Leqembi

According to a report by RTTNews dated September 1, 2026, Canada’s national drug agency has recommended public reimbursement of Leqembi for patients with early Alzheimer disease, a product developed by Biogen and its partner Eisai.

The RTTNews overview notes that in overnight trading on September 1, 2026, Biogen stock was up about 1.2 percent at a price of 219.17 USD, reflecting investor optimism that broader access in Canada could strengthen the commercial trajectory of Leqembi and support Biogen’s neurodegeneration franchise.

Earnings and valuation context for Biogen stock

For investors assessing Biogen’s fundamentals, a recent valuation update compiled by GuruFocus on August 31, 2026 highlights that Biogen’s share price of 217.68 USD at that point stood about 11.3 percent above an estimated intrinsic value of 195.62 USD per share derived from the platform’s GF Value model, indicating a modest premium in the market.

While the valuation analysis does not detail the latest quarterly figures, it frames Biogen as a company where current earnings and cash flows have led to a fair value estimate below the prevailing share price, which investors will weigh against pipeline optionality and regulatory milestones such as the Canadian reimbursement decision for Leqembi.

Leqembi as a key Biogen product

Leqembi, the Alzheimer drug at the center of the Canadian reimbursement decision, is one of Biogen’s most important late stage products because it targets early Alzheimer disease, a large patient population that historically had limited disease modifying treatment options.

With public reimbursement recommended in Canada for appropriate early stage patients, the drug’s revenue potential in that market improves and adds to sales already emerging from other regions, making Leqembi a central component of Biogen’s growth story in neurodegenerative diseases.

Biogen stock price snapshot

As summarized by RTTNews on September 1, 2026, Biogen stock was quoted at 219.17 USD in overnight trading, which stands slightly above the 217.68 USD level cited in the GuruFocus valuation analysis published on August 31, 2026, underscoring that the shares have moved about 0.7 percent higher in that short interval as investors digested the Canadian reimbursement news.

Biogen Inc. stock facts

• Company: Biogen Inc.
• ISIN: US09062X1037
• Ticker: BIIB
• Trading venue: Nasdaq
• Price (as of September 1, 2026): 219.17 USD
• Market capitalization: not specified (as of latest available data)
• Sector / Industry: Biotechnology
• Index membership: S&P 500